AIMS: To compare outcome of AF patients with effective rhythm control with patients treated with rate control. METHODS AND RESULTS: Out of the 266 AF patients randomized to rhythm control in the RACE study, 49 patients turned to long-term sinus rhythm and were continuously treated withoral anticoagulation. The incidence of the primary endpoint in these patients was compared to that in 178 patients out of the initial 256 rate-control patients of RACE who were in AF and using oral anticoagulation continuously. Baseline characteristics of both groups were not different. After a mean follow-up of 2.3+/-0.6 years, the primary endpoint (a composite of cardiovascular mortality, heart failure, thrombo-embolic complications (TECs), bleeding, serious adverse effects of antiarrhythmic drugs and pacemaker implants) was 22.4% in the rhythm-control group vs. 15.2% in the rate-control group. Multivariable regression analysis indicated coronary artery disease, heart failure, and digitalis as independent risk indicators of cardiovascular morbidity and mortality. Chronic sinus rhythm did not matter. CONCLUSION: Among patients who remained on warfarin, those who mostly were maintained in sinus rhythm under a rhythm-control strategy did not have a superior prognosis compared to those who remained in AF under a rate-control strategy.
RCT Entities:
AIMS: To compare outcome of AFpatients with effective rhythm control with patients treated with rate control. METHODS AND RESULTS: Out of the 266 AFpatients randomized to rhythm control in the RACE study, 49 patients turned to long-term sinus rhythm and were continuously treated with oral anticoagulation. The incidence of the primary endpoint in these patients was compared to that in 178 patients out of the initial 256 rate-control patients of RACE who were in AF and using oral anticoagulation continuously. Baseline characteristics of both groups were not different. After a mean follow-up of 2.3+/-0.6 years, the primary endpoint (a composite of cardiovascular mortality, heart failure, thrombo-embolic complications (TECs), bleeding, serious adverse effects of antiarrhythmic drugs and pacemaker implants) was 22.4% in the rhythm-control group vs. 15.2% in the rate-control group. Multivariable regression analysis indicated coronary artery disease, heart failure, and digitalis as independent risk indicators of cardiovascular morbidity and mortality. Chronic sinus rhythm did not matter. CONCLUSION: Among patients who remained on warfarin, those who mostly were maintained in sinus rhythm under a rhythm-control strategy did not have a superior prognosis compared to those who remained in AF under a rate-control strategy.
Authors: Michiel Rienstra; Steven A Lubitz; Saagar Mahida; Jared W Magnani; João D Fontes; Moritz F Sinner; Isabelle C Van Gelder; Patrick T Ellinor; Emelia J Benjamin Journal: Circulation Date: 2012-06-12 Impact factor: 29.690
Authors: D George Wyse; Isabelle C Van Gelder; Patrick T Ellinor; Alan S Go; Jonathan M Kalman; Sanjiv M Narayan; Stanley Nattel; Ulrich Schotten; Michiel Rienstra Journal: J Am Coll Cardiol Date: 2014-02-12 Impact factor: 24.094
Authors: Mariëlle Kloosterman; Jonas Oldgren; David Conen; Jorge A Wong; Stuart J Connolly; Alvaro Avezum; Salim Yusuf; Michael D Ezekowitz; Lars Wallentin; Marie Ntep-Gweth; Philip Joseph; Tyler W Barrett; Supachai Tanosmsup; William F McIntyre; Shun Fu Lee; Ratika Parkash; Guy Amit; Alex Grinvalds; Isabelle C Van Gelder; Jeff S Healey Journal: Europace Date: 2020-06-01 Impact factor: 5.214
Authors: Meelad I H Al-Jazairi; Bao-Oanh Nguyen; Ruben R De With; Marcelle D Smit; Bob Weijs; Anne H Hobbelt; Marco Alings; Jan G P Tijssen; Bastiaan Geelhoed; Hans L Hillege; Robert G Tieleman; Dirk J Van Veldhuisen; Harry J G M Crijns; Isabelle C Van Gelder; Yuri Blaauw; Michiel Rienstra Journal: Europace Date: 2021-09-08 Impact factor: 5.214